lupus.bmj21h
LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis
3 Division of Rheumatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA 4 Division of Rheumatology, Allergy and Immunology, University of California San ...
lupus.bmj1d
Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival
Objectives While diffuse alveolar haemorrhage (DAH) is recognised as a life-threatening complication of systemic lupus erythematosus (SLE), little is known about its risk factors and response to ...
lupus.bmj4d
Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study
Objective It is still unclear how glucocorticoids (GCs) affect the long-term clinical course of patients with SLE. The objective of this study is to explore the factors associated with GC-free ...
lupus.bmj5d
Exacerbating effects of circadian rhythm disruption on the systemic lupus erythematosus
Objective Circadian rhythm disruption (CRD) has been associated with inflammation and immune disorders, but its role in SLE progression is unclear. We aimed to investigate the impact of circadian ...
lupus.bmj2d
Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE
Objective Patients with SLE have an increased risk of atherosclerosis (ATH) that is not adequately explained by traditional risk factors. We previously described the Predictors of Risk for Elevated ...
lupus.bmj7d
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases
Objective Systemic autoimmune rheumatic diseases (SARDs) encompass a diverse group of complex conditions with overlapping clinical features, making accurate diagnosis challenging. This study aims to ...
lupus.bmj8d
Using photovoice to investigate patient experiences of lupus nephritis in Canada
Objective Lupus nephritis (LN) is a major cause of morbidity and mortality, affecting up to 60% of patients with systemic lupus erythematosus (SLE). The perspectives of patients with SLE have been ...
lupus.bmj4d
29 Treatment of CAPS: which drugs and in which order?
Describe why combination of anticoagulation and corticosteroids is the cornerstone treatment of CAPS and that life-threatening CAPS episodes should be treated with a triple-therapy including ...
lupus.bmj6d
O7 Safety of chloroquine and hydroxychloroquine during pregnancy: a systematic literature review and meta-analysis
Background Some countries face restrictions to prescribe Chloroquine (CQ) and Hydroxychloroquine (HCQ) during pregnancy, due to report of ocular toxicity in rodents and potential genotoxicity. The aim ...
lupus.bmj10d
LSO-003 Effects of progesterone-induced blocking factor 1 on the alleviation of lupus nephritis in MRL/lpr mice
1 Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Republic of Korea 2 Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, ...
lupus.bmj1d
Assessing QT interval in patients with autoimmune chronic inflammatory diseases: perils and pitfalls
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...